Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

Mostrar otras versiones (1)

BACKGROUND: Overexpression of p185HER2 is an established poor prognostic factor in breast cancer, portending an aggressive course and potential for early metastasis. On the other hand, monoclonal antibody trastuzumab is widely used in the clinic to target this overexpressed oncogene. Unfortunately,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tural, D, Serdengecti, S, Demirelli, F, Öztürk, T, İlvan, S, Turna, H, Özgüroglu, M, Büyükünal, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992510/
https://www.ncbi.nlm.nih.gov/pubmed/24595002
http://dx.doi.org/10.1038/bjc.2014.72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992510/
https://www.ncbi.nlm.nih.gov/pubmed/24595002
http://dx.doi.org/10.1038/bjc.2014.72

Ejemplares similares